U.S., Feb. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07384013) titled 'Study Protocol: Impact of Metamizole (Optalgin(R)) on Anti-Xa Concentrations in Oncology Patients Receiving DOACs' on Sept. 25, 2025.
Brief Summary: Evaluation of the Effect of metamizole (Optalgin(R)) on Anti-Xa Levels in Oncology Patients Receiving Direct Oral Anticoagulants (DOACs)
Study Start Date: Nov. 01, 2025
Study Type: INTERVENTIONAL
Condition:
Oncologic Diseases
Coagulation Defect
Pain Management
Intervention:
DRUG: metamizole
chronic metamizole use
DRUG: metamizole
New metamizole users
Recruitment Status: RECRUITING
Sponsor: Rambam Health Care Campus
Published by HT Digital Content Services with permission from...